Since our newly identified MAPK4-PDK1 axis can work with the MAPK4-AKT axis to promote cancer growth, we examined whether co-targeting PDK1 and AKT using PDK1 inhibitor GSK2334470 and AKT inhibitor MK2206 will be a valid approach to block MAPK4 tumor-promoting activities. Here, PDK1 is linked to neoplasm.